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Objectives: Numerous studies have documented a relationship between provider variables, including surgeon volume and
specialty, and outcomes for surgical procedures. In this study we analyzed claims data from a Medicare database to analyze
outcomes of sacral neuromodulation (SNM) with respect to both provider and patient factors.
Materials and Methods: A 5% random sample of Medicare beneﬁciaries from 1997 to 2007 was the data source. Data retrieved
included demographic information, ICD-9 diagnosis codes, and CPT procedure codes. Multivariate analysis was performed to
identify predictors of progression to implantable pulse generator (IPG) implantation.
Results: After stage I testing, urologists were more likely than gynecologists to proceed to IPG placement (Center for Medicare
and Medicaid Services: 49% vs. 43%, p < 0.0001). After percutaneous testing, gynecologists were more likely than urologists to
proceed to battery placement (63% vs.44%, p = 0.005). Among the patient variables analyzed, women were more likely than men
to progress to battery placement. Patients treated by high-volume providers had higher rates of IPG placement after formal stage
I trials (71% vs. 33%, p < 0.0001).
Conclusions: The rate of IPG implantation after SNM was greater among high-volume providers. Women had better outcomes
thanmen. Further researchmay better deﬁne the relationship between outcomes of sacral neuromodulation and speciﬁc etiology
of voiding dysfunction.
Keywords: Claims data, InterStim, provider specialty, provider volume
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INTRODUCTION
Numerous studies have documented a relationship between pro-
vider variables, including surgeon volume and specialty, and out-
comes for surgical procedures. Volume, or case load, has been used
as a surrogate for quality of care in many diseases and is easily
abstracted and analyzed. Studies evaluating postoperative morbid-
ity and mortality have shown that high-volume hospitals oﬀer
better outcomes for vascular surgery, liver transplantation, and
major cancer surgery (1–4). The urologic literature has also demon-
strated that the rates of postoperative and late urinary complica-
tions after radical prostatectomy are signiﬁcantly reduced if the
procedure is performed in a high-volume hospital and by a surgeon
who performs a large number of such procedures (5–8).
Surgeon specialty has also been shown to have an eﬀect on out-
comes (9–11). McKenna et al. demonstrated that patients who
underwent surgical excision of cutaneous melanoma by a derma-
tologist or a surgical oncologist had lower recurrence rates than
those who had their excision by a general surgeon (11). In a Medi-
care claims analysis of pubovaginal sling outcomes, we previously
found that gynecologists were more likely than urologists to
perform concomitant prolapse surgery, thereby reducing early
re-operation rates for prolapse (12).
Sacral neuromodulation (SNM) is Food and Drug Administration-
approved for many types of voiding dysfunction refractory to
medical therapy. It involves the placement of a small lead in the
third sacral foramen, adjacent to the S3 nerve root, connected to an
implantable pulse generator (IPG) placed in the buttock area (13). It
serves as a bladder “pacemaker” that modulates S3-related neural
pathways and improves voiding dysfunction of many etiologies,
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including overactive bladder symptoms (both “wet” and “dry”),
urinary retention, and pelvic pain associatedwith urinary frequency.
Patients undergo a short (one- to two-week) period of testing
before proceeding with permanent pulse generator placement.
Testing can either be with a permanent lead (formal stage I testing)
or a temporary wire that is then replaced with a permanent lead
after the testing period (percutaneous test) (13).
In order to understand patterns of care for patients undergoing
SNM for various types of voiding disorders, we recently analyzed
data from a 5% random sample ofMedicare beneﬁciaries (13). In this
analysis, we speciﬁcally sought to evaluate the diﬀerences in rates of
IPG implantation with respect to both provider specialty and
volume. We also analyzed patient variables, including age, gender,
race, and chief diagnosis for which SNM was performed.
MATERIALS AND METHODS
Medicare claims provide the billing information of claims for ser-
vices among Medicare beneﬁciaries in the United States. We
obtained Medicare claims data from the Center for Medicare and
Medicaid Services Public Use Files, as previously described (13). We
used a 5% national random sample of Medicare beneﬁciaries from
1997 to 2007. Previous studies provide internal validation for similar
research using 5% Medicare public use administrative data (14–16).
Each patient was linked by a unique patient identiﬁer. All patients
were therefore de-identiﬁed, and this work was granted an institu-
tional review board exemption from the University of California, Los
Angeles and RAND. CPT codes identiﬁed relevant procedures per-
formed on each individual, and ICD-9 diagnosis codes identiﬁed the
indication, as previously described (13). We categorized patients
with overactive bladder (OAB)-dry as those diagnosed with either
urgency of urination (ICD-9 code 788.63), urinary frequency
(788.41), bladder hypertonicity (596.51), detrusor instability
(596.59), or nocturia (788.43). Thosewith OAB-wet included patients
with a diagnosis of unspeciﬁed urinary incontinence (788.30), urge
incontinence (788.31), and mixed incontinence (788.33). Patients
were also grouped into neurogenic voiding dysfunction, interstitial
cystitis, or “other” voiding dysfunction categories, according to rel-
evant diagnosis codes (13).
Lead placement was categorized into percutaneous lead place-
ment (CPT-4 code 64561) and operative lead placement (stage I,
CPT-4 code 64581). Implantation was deﬁned as a patient proceed-
ing to battery implantation (CPT-4 code 64590). We compared out-
comes by provider volume and specialty (urology vs. gynecology).
All implanting physicians were stratiﬁed based on number of cases
performed over the 1997–2007 time period. High-volume providers
were deﬁned as those who were in the upper 25th percentile of
number of procedures performed, which corresponded to 5+ pro-
cedures. Descriptive statistics were used to report IPG implantation
rates. Patient variables analyzed included age, gender, race, and
chief diagnosis for which SNM was performed. Multivariate analysis
was performed to control for covariates and identify predictors of
outcomes. The chi-square test was used to compare implantation
rates based on the patient and provider variables. Statistical analysis
was performed using Statistical Analysis System (SAS®).
RESULTS
In the 1997–2007 5%Medicare sample, 1132 patients underwent
staged (operative) lead placement for test stimulation, and 358
underwent percutaneous test stimulation. Caucasians represented
91.3% of patients, and 73.6% were female (13); 35.4% of the staged
tests and 45.8% of the percutaneous tests were found to be success-
ful, as deﬁned by proceeding to battery implantation (13).
The most common associated ICD-9 diagnosis code was “wet” or
“dry” OAB (63.0%), followed by “other” indications (21.7%), urinary
retention (9.5%), neurogenic bladder (3.2%), and interstitial cystitis
(2.6%). Forty-six percent of the percutaneous tests and 35.4% of the
staged tests resulted in placement of a permanent IPG. Implantation
rates were greater in women than in men (43.7% vs. 29.3%, p <
0.0001). As previously described, patients underwent reprogram-
ming an average of 2.15 times in their ﬁrst year, with that number
decreasing over subsequent years. Of 558 batteries implanted, 63
(11.3%) were explanted (17).
The top quartile for procedure volumewas at least ﬁve cases in 10
years. Physicians in the top quartile performed 35.1% of all cases
(176 percutaneous trials and 240 operative trials) and those in the
lower three quartiles performed 64.9% of cases (174 percutaneous
trials and 595 operative trials). In multivariate analysis, physicians in
the top quartile were more likely to progress to IPG placement than
those in the lower three quartiles (Table 1). Urologists performed
64.7% of cases (305 percutaneous trials and 670 operative trials),
and 13.9%were performed by gynecologists (49 percutaneous trials
and 161 operative trials). Urologists had better outcomes after
operative trials (higher rates of IPG placement) than gynecologists
in both datasets (49% vs. 43%, p < 0.0001). However, gynecologists



























Urologist 305 44.3 45.6 6.9 3.3 0.0046 670 46.2 50.6 <0.0001 48.8
Gynecologist 49 63.2 34.7 0 2.0 161 37.3 62.7 43.3
Other 12 8.3 91.7 0 0 311 11.3 88.7 11.1
Total 366 45.6 45.6 5.7 3.0 1142 35.5 62.7 39.9
Volume
High 176 43.2 48.3 5.7 2.8 0.6937 240 71.3 24.6 <0.0001 63.3
Low 174 48.9 42.0 6.3 2.9 595 33.1 65.0 38.7
Total 350 46.0 45.1 6.0 2.9 835 44.1 53.4 47.3
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had better outcomes of percutaneous testing (63% vs. 44%, p =
0.005). Multivariate analysis conﬁrmed a higher rate of IPG place-
ment overall among urologists (Table 2).
IPG implantation rates were greater among female patients than
male patients (41.6 vs. 27.7%, p < 0.0001), and multivariate analysis
conﬁrmed a nearly twofold diﬀerence in outcomes between sexes.
Patients with OAB-dry had worse overall outcomes than those with
OAB-wet. Older patients (>55 years) had a lower rate of IPG implan-
tation after formal staged trials but a higher rate of IPG placement
after percutaneous trial.
DISCUSSION
This Medicare 5% sample identiﬁed a relationship between pro-
vider variables and conversion rates, as measured by proceeding to
IPG implantation. Patients who underwent surgical placement of a
lead for test stimulation by a high-volume provider were overall 2.7
times as likely to proceed to IPG implant as those who had their lead
placement by a low-volume provider. This could be due to one of
many possible factors. It is possible that high-volume providers
achieve a better response owing to surgical technique that maxi-
mizes patient response, resulting in a better outcome. The clinical
characteristics of patients seen by high-volume providers may also
be diﬀerent and more favorable for a positive outcome with sacral
neuromodulation. Alternatively, high-volume providers may be
more likely to proceed to stage II in patients whose response is
borderline, thereby increasing the rate of battery placement
without necessarily having better surgical technique over low-
volume providers. However, our results could have also been partly
due to physician learning curve. In Medicare, physicians in the lower
three quartiles did fewer than 5 procedures in 11 years. They may
have still been in the learning curve, whichmay have contributed to
the outcomes we observed.
Patients who underwent lead placement by a urologist were
more likely to proceed to battery placement. We previously exam-
ined the provider–specialty relationship in sling surgery for stress
incontinence, and found that patients who underwent a sling by a
gynecologist had a lower rate of re-operation for prolapse within
one year of the sling (12). This was due to the fact that gynecologists
were more likely to perform concomitant prolapse surgery at the
time of the sling. The provider–specialty relationship is more diﬃ-
cult to deﬁne with sacral neuromodulation, as conversion rate, as
deﬁned by permanent IPG placement, is a function of subjective
surgeon and patient decision-making. The majority of lead place-
ments were performed by urologists. The fact that outcomes were
better among urologists may be due to that fact that there were
more high-volume providers among urologists than gynecologists.
The diﬀerences in outcomes between specialties, if real, will likely
diminish as sacral neuromodulation spreads throughout the gyne-
cologic community.
Female patients had better outcomes than men. A relationship
between patient gender and outcomes of sacral neuromodulation
has been found in previous case series (18), but this ﬁnding is not
consistent in the literature (19). It may be that urge incontinence
and other voiding disorders are more diﬃcult to treat in men, pos-
sibly relating to the long-term eﬀects of prostatic obstruction on the
bladder. Patients with OAB-wet had better outcomes than those
with OAB-dry, a ﬁnding that has been supported in clinical series
(20). Overall rates of IPG implantation were much lower than
observed in published clinical series. This suggests that real-world
outcomes are inferior to those of experts in the ﬁeld who publish
such series (18–22). The main reason for not progressing to IPG
placement is a suboptimal response in the test phase. This may be
technical, in that the lead or wire is in a suboptimal location; it might
be due to surgeons’ accepting only partial responses in the operat-
ing room, rather than attempting to get all three responses (levator
bellows, toe response, and sensation) in all four leads; or it may be
due to patient selection in which patients do not respond despite
optimal intraoperative responses. Our ﬁndings may therefore give
more accurate information to providers so that patients can be
counseled with realistic expectations when proceeding with
InterStim.
In addition, IPG implantation was higher in the groups who
underwent formal stage I placement of the lead. This ﬁnding corre-
lates with clinical series in the literature (18–22). The most likely
explanation is the fact that the percutaneous wire may easily
migrate after the percutaneous trial. However, other unmeasurable
factors could account for the decision to proceed with IPG implan-
tation. For example, providers and patients may feel more invest-
ment in proceeding to IPG implantation after formal stage I testing,
leading to a higher rate of IPG placement. A related issue is that
percutaneous testing is less invasive, so it may be oﬀered to (and
accepted by) patients who are not as bothered by their symptoms
Table 2. Multivariate Analysis of Outcomes Based on Provider and Patient Variables.
Measured variable Successful percutaneous test Successful two-stage, no percutaneous test Overall success
Odds ratio 95% CI Odds ratio 95% CI Odds ratio 95% CI
High surgeon volume vs. low 0.768 0.476 1.241 5.019 3.573 7.050 2.743 2.123 3.543
Urologist vs. gynecologist 0.749 0.387 1.451 1.470 0.999 2.162 1.575 1.149 2.160
White vs. nonwhite 1.842 0.667 5.090 0.705 0.399 1.246 0.820 0.511 1.316
Female vs. male 2.882 1.566 5.305 1.620 1.108 2.368 1.861 1.379 2.512
Age 55 or less vs. older than 55 0.108 0.054 0.215 2.036 1.488 2.786 1.042 0.805 1.347
Other diagnoses vs. wet
overactive bladder
Neurogenic bladder 0.836 0.267 2.619 1.497 0.685 3.273 1.342 0.722 2.496
Interstitial cystitis 1.913 0.435 8.414 0.416 0.173 1.002 0.829 0.412 1.670
Urinary retention 0.807 0.401 1.624 0.925 0.565 1.514 0.967 0.656 1.427
Dry overactive bladder 0.615 0.348 1.089 0.786 0.552 1.119 0.731 0.551 0.971
Odds ratio (OR) measures the eﬀect size of the measured variable. OR > 1 means better success than comparison group, and OR < 1 means less success. The
magnitude of the OR correlates with the strength of the association (i.e., the bigger the OR, the greater the eﬀect of the measured variable).
A 95% conﬁdence interval (CI) that crosses 1 is not considered statistically signiﬁcant.
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and/or not as motivated to intervene, compared with patients who
undergo stage I. Regardless, the poor conversion rate of percutane-
ous trials leads us to question their use over formal lead placement.
The fact that younger age predicted better outcomes after formal
stage I placement but not percutaneous testingmay also reﬂect the
inaccuracies of percutaneous testing.
Claims-based data provide knowledge about real-world practice
patterns and outcomes. However, such data have inherent limita-
tions that relate to the lack of clinical information present. We were
not able to assess the degree of success among patients, but rather
were conﬁned to measuring conversion rate by IPG placement.
Claims data do not give any clinical information about patient
symptom reduction, and patients can have devices implanted that
are ineﬀective. Though lead placement is often considered success-
ful, and a battery is implanted if a patient is improved by 50% or
more (21), there is tremendous variation in how improvement is
measured objectively by the physician and subjectively by the
patient. In addition, gynecologists are more likely to treat women
(though some do perform neuromodulation on men, which could
have impacted our gender-speciﬁc ﬁndings). Lastly, the Medicare
population is older, and may not reﬂect the entire population of
patients undergoing sacral neuromodulation.
CONCLUSION
Conversion rate of sacral neuromodulation, as deﬁned by implan-
tation of a permanent IPG, was greater among high-volume provid-
ers and urologists. This suggests that technical factors, including the
use of an operative (staged) testing approach, play a role in improv-
ing outcomes. Although women had better outcomes than men,
there was variation in outcomes by patient age and diagnosis.
Further research may better deﬁne the relationship between out-
comes of sacral neuromodulation and speciﬁc etiology of voiding
dysfunction.
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COMMENT
In this study based on a sample survey of Medicare claims, the rate
of IPG implantation following a screening trial was shown to be higher
among “high volume providers”. High volume was deﬁned as implant-
ers having performed 5 or more procedures over a ten year period,
which obviously does not guarantee proﬁciency. Furthermore, the
authors are correct to point out that the decision to proceed to an
implant may be variable and subjective, and the “conversion rate”does
not equal success of the therapy. Still, the rate of conversion was found
to be higher after a staged trial and for patients with wet versus dry
OAB. Both of these observations correlate with clinical series in the
literature, underscoring the potential soundness of the methodology.
A future survey conducted over a time period exclusively using
modern techniques (tined-lead, ﬂuoroscopic guidance, minimal anes-
thesia), with a more experienced surgeon base, and with more atten-
tion to measures that deﬁne post-implant success of the therapy could
lead to more meaningful conclusions.
Steven Siegel, MD
Woodbury, MN, USA
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